Amneal Pharmaceuticals annual depreciation and amortization
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amneal Pharmaceuticals Depreciation & Amortization Growth & History (AMRX)
Amneal Pharmaceuticals's depreciation and amortization was $223.6M for fiscal 2025.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $223.6M | −$12.6M | −5.33% |
| 2024 | 2024-12-31 | $236.2M | $6.8M | +2.96% |
| 2023 | 2023-12-31 | $229.4M | −$10.8M | −4.50% |
| 2022 | 2022-12-31 | $240.2M | $6.8M | +2.91% |
| 2021 | 2021-12-31 | $233.4M | −$2.0M | −0.84% |
| 2020 | 2020-12-31 | $235.4M | $28.2M | +13.58% |
| 2019 | 2019-12-31 | $207.2M | −$1.1M | −0.54% |
| 2018 | 2018-12-31 | $208.4M | $93.4M | +81.27% |
| 2017 | 2017-12-31 | $114.9M | $81.9M | +248.16% |
| 2016 | 2016-12-31 | $33.0M | — | — |
Amneal Pharmaceuticals quarterly depreciation and amortization
Q2.17
Q3.17
Q2.18
Q3.18
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $47.8M | −$12.3M | −20.48% |
| Q1 2026 | 2026-03-31 | $43.2M | — | — |
| Q4 2025 | 2025-12-31 | $49.2M | — | — |
| Q3 2025 | 2025-09-30 | $54.1M | — | — |
| Q2 2025 | 2025-06-30 | $60.1M | — | — |
| Q3 2018 | 2018-09-30 | $43.0M | $31.1M | +259.70% |
| Q2 2018 | 2018-06-30 | $32.1M | $21.6M | +205.12% |
| Q3 2017 | 2017-09-30 | $12.0M | — | — |
| Q2 2017 | 2017-06-30 | $10.5M | — | — |
Amneal Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Amneal Pharmaceuticals's depreciation and amortization decreased from $235.4M to $223.6M, a change of −$11.8M. The latest reported quarter, Q2 2026, shows $47.8M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amneal Pharmaceuticals source filings ↗